AIP
CRNX

Ameritas Investment Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ameritas Investment Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
9,412
+1,322
+16% +$49.1K 0.01% 1051
2026
Q1 		$294K Buy
8,090
+750
+10% +$33.5K 0.01% 1051
2025
Q4 		$342K Sell
7,340
-215
-3% -$9.57K 0.01% 967
2025
Q3 		$315K Sell
7,555
-1,619
-18% -$51.8K 0.01% 995
2025
Q2 		$264K Hold
9,174
– – 0.01% 1141
2025
Q1 		$308K Hold
9,174
– – 0.01% 1031
2024
Q4 		$469K Buy
9,174
+1,291
+16% +$72.2K 0.02% 864
2024
Q3 		$403K Buy
7,883
+260
+3% +$13.4K 0.01% 922
2024
Q2 		$341K Buy
7,623
+864
+13% +$39.9K 0.01% 955
2024
Q1 		$316K Hold
6,759
– – 0.01% 1003
2023
Q4 		$240K Buy
6,759
+282
+4% +$8.65K 0.01% 1154
2023
Q3 		$193K Buy
6,477
+2,490
+62% +$51.3K 0.01% 1200
2023
Q2 		$71.8K Hold
3,987
– – ﹤0.01% 1814
2023
Q1 		$64K Hold
3,987
– – ﹤0.01% 1822
2022
Q4 		$79.3K Hold
3,987
– – ﹤0.01% 1751
2022
Q3 		$78K Hold
3,987
– – ﹤0.01% 1673
2022
Q2 		$74K Buy
3,987
+425
+12% +$8.48K ﹤0.01% 1708
2022
Q1 		$78K Hold
3,562
– – ﹤0.01% 1788
2021
Q4 		$101K Buy
3,562
+702
+25% +$17.3K ﹤0.01% 1675
2021
Q3 		$60K Hold
2,860
– – ﹤0.01% 2032
2021
Q2 		$54K Buy
2,860
+470
+20% +$8.26K ﹤0.01% 2123
2021
Q1 		$37K Hold
2,390
– – ﹤0.01% 2254
2020
Q4 		$34K Hold
2,390
– – ﹤0.01% 2202
2020
Q3 		$37K Hold
2,390
– – ﹤0.01% 2021
2020
Q2 		$42K Buy
2,390
+1,438
+151% +$24.5K ﹤0.01% 1936
2020
Q1 		$14K Hold
952
– – ﹤0.01% 2363
2019
Q4 		$24K Hold
952
– – ﹤0.01% 2314
2019
Q3 		$14K Hold
952
– – ﹤0.01% 2572
2019
Q2 		$24K Buy
952
+378
+66% +$9.36K ﹤0.01% 2338
2019
Q1 		$13K Hold
574
– – ﹤0.01% 2591
2018
Q4 		$17K Hold
574
– – ﹤0.01% 2430
2018
Q3 		$16K Buy
+574
New +$17K ﹤0.01% 2610

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameritas Investment Partners's CRNX Position: Q2 2026 in Review

Ameritas Investment Partners increased its Crinetics Pharmaceuticals (CRNX) stake by 16% in Q2 2026, buying an estimated $49.1K and bringing the position to 9,412 shares worth $352K. The position accounts for 0.01% of the portfolio, ranked #1051.

Ameritas Investment Partners first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $469K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Ameritas Investment Partners held 9,412 shares of Crinetics Pharmaceuticals worth $352K as of Q2 2026.
  • Ameritas Investment Partners bought 1,322 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $49.1K.
  • Crinetics Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1051 holding.
  • Ameritas Investment Partners first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Ameritas Investment Partners's Crinetics Pharmaceuticals position peaked at $469K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.